CN113712992A - 含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 - Google Patents
含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 Download PDFInfo
- Publication number
- CN113712992A CN113712992A CN202111025423.5A CN202111025423A CN113712992A CN 113712992 A CN113712992 A CN 113712992A CN 202111025423 A CN202111025423 A CN 202111025423A CN 113712992 A CN113712992 A CN 113712992A
- Authority
- CN
- China
- Prior art keywords
- inulin
- parts
- vitamin
- hydrogen
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001202 Inulin Polymers 0.000 title claims abstract description 35
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 title claims abstract description 35
- 229940029339 inulin Drugs 0.000 title claims abstract description 35
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 239000001257 hydrogen Substances 0.000 title claims abstract description 28
- 229910052739 hydrogen Inorganic materials 0.000 title claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000008280 blood Substances 0.000 title claims abstract description 21
- 210000004369 blood Anatomy 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 12
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 10
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 10
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 9
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 8
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 7
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 230000001603 reducing effect Effects 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000723343 Cichorium Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用。含菊粉的益生元包括菊粉、低聚半乳糖、β－葡聚糖、低聚果糖、维生素C、维生素B2、维生素B6。本发明将含菊粉的益生元与富氢水联用，菊粉益生元产品有益于血糖控制，氢气通过氧化作用降低炎症，与菊粉益生元发挥协同作用，降糖效果明显。
Description
技术领域
本发明涉及含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用。
背景技术
目前，糖尿病的主流治疗方法是药物治疗和中医疗法。药物治疗的优势在于效果好，见效快；缺点在于指标不治本，仅仅是针对血糖进行控制，而且是终生用药，易产生耐药性和药物副作用等。中医疗法优势在于副作用较小，针对根源性问题进行治疗；缺点是时间长见效慢，效果不一定有保证。
近年来，学者们发现益生元可用于预防和治疗糖尿病，成为糖尿病医学营养治疗的有效措施。菊粉、低聚果糖和低聚半乳糖等是水溶性膳食纤维，因其具有不被人体所消化吸收，但可以被肠道微生物利用发酵，促进有益菌群的生长和代谢能力，有利于促进控制血糖和血脂，但是菊粉益生元对糖尿病患者降糖的效果还需要进一步提高。
发明内容
本发明提供一种含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用。
本发明将含菊粉的益生元与富氢水联用，所述的含菊粉的益生元包括菊粉、低聚半乳糖、β－葡聚糖、低聚果糖、维生素C、维生素B2、维生素B6。
进一步的，所述的含菊粉的益生元包括以下重量份数的各组分：
菊粉250～300份、低聚半乳糖100～150份、β－葡聚糖80～120份、低聚果糖80～120份、维生素C 30-80份、维生素B2 3～8份和维生素B63～8份。
进一步的，所述的含菊粉的益生元包括以下重量份数的各组分：
菊粉280份、低聚半乳糖120份、β－葡聚糖100份、低聚果糖100份、维生素50份、维生素B25份和维生素B65份。
氢气作为一种有一定还原性的双原子分子，其具有极强的自由扩散能力，在体内有选择性地抗氧化、抑制炎症反应、抗细胞凋亡等作用。氢气增加了细胞超氧化物歧化酶和血清脂联素水平，改善了患者的胰岛素抵抗。氢气不仅对于2型糖尿病和糖耐量异常患者的糖代谢有改善作用，对于糖尿病患者因高血糖引起的其他并发症也有一定的保护作用。
菊粉:菊苣提取物是通过改善肠道菌群的数量或结构降低炎症以及发挥膳食纤维作用延缓餐后血糖上升而发挥降糖作用。
维生素C：可以保护其它抗氧化剂，如维生素A、维生素E，防止自由基对人体的伤害。可促进胆固醇的排泄，防止胆固醇在动脉内壁沉积，甚至可以使沉积的粥样斑块溶解。
低聚半乳糖:调节肠道菌群平衡,提高机体免疫力；增加超氧化物歧化酶(SOD)活性和含量，抑制炎症反应。
低聚果糖:对肠道益菌的增殖作用；主要是双歧杆菌和乳杆菌，其作用机制同低聚半乳糖。还可有效调节人体胰岛素抵抗状态,可辅助降糖药物更好的发挥降糖效果,可减弱C反应蛋白对胰岛素信号的传导途径，继而调节人体胰岛素抵抗作用。
β－葡聚糖:β-葡聚糖通过保护和修复胰岛β细胞、改善胰岛素抵抗和糖代谢等来调节血糖。
维生素B2：B族维生素以辅酶的身份参与体内糖、蛋白质、脂肪代谢。
维生素B6：B族维生素以辅酶的身份参与体内糖、蛋白质、脂肪代谢。
本发明所达到的有益效果是：本发明将含菊粉的益生元与富氢水联用，菊粉益生元产品有益于血糖控制，氢气通过氧化作用降低炎症，与菊粉益生元发挥协同作用，降糖效果明显。
具体实施方式
以下对本发明的优选实施例进行说明，应当理解，此处所描述的优选实施例仅用于说明和解释本发明，并不用于限定本发明。
实施例
含菊粉的益生元包括以下重量份数的各组分：
菊粉280份、低聚半乳糖120份、β－葡聚糖100份、低聚果糖100份、维生素50份、维生素B25份和维生素B65份。按以上比例混合均匀，配成20g/袋产品。
富氢水：富氢水(0.6mmol)的制备：将纯度为99.9％的金属镁棒置入含有500mL日常饮用水的聚丙烯瓶中，拧紧瓶盖保持12h后饮用，镁棒可以重复利用。ENH-1000氢气检测计测定浓度。项目组成员每天会把富氢水送到参与者手中，按300mL/d现场饮用，5min内喝完。分两次饮水，间隔为12h。由专人监督并登记，持续30d。
随机选取2型糖尿病患者70人(糖化血红蛋白大于8.0％)，每组10人。参与者的降糖药不受其他影响，实验期内用量不变。
对照组：参与者按照正常生活方式不加干预。
实施组一：参与者一天使用益生元产品一袋，固定晚餐前半小时食用。不喝富氢水。
实施组二：参与者一天不食用益生元产品。富氢水300mL/d。
实施组三：参与者一天使用益生元产品一袋，固定晚餐前半小时食用。富氢水300mL/d。
从以上数据分析分析得出，益生元产品和富氢水联用干预血糖效果远大于单一使用的效果。
从以上数据分析分析得出，添加富氢水试验组在抗炎和抗氧化作用上效果明显突出。富氢水通过抗氧化降低炎症反应干预血糖。
MDA是强氧化自由基攻击细胞质膜中的多不饱和脂肪酸形成的脂质过氧化产物，MDA增加说明机体处于高氧化状态，发生糖尿病并发症的危险性较高。
ROS本身就是糖尿病氧化应激过程的产物，包括超氧阴离子、羟自由基和过氧化氢等，具有很强的氧化能力，能够导致脂质、蛋白质甚至DNA的损伤，增加糖尿病并发症的风险。
GSH-PX和SOD代表体内的抗氧化能力，SOD催化超氧阴离子生成过氧化氢，GSH-PX则继续催化过氧化氢生成水，清除体内ROS。
从以上数据分析分析得出，添加益生元试验组在肠道菌群干预变哈啊较大，促进益生菌生长，从而改善肠道菌群降低炎症。富氢水通过抗氧化降低炎症反应干预血糖。
从以上所有数据可以分析得出，加入菊粉益生元产品有益于血糖控制。同时加入富氢水的数据表明，氢气通过氧化作用降低炎症，与菊粉益生元发挥协同作用，降糖效果明显。
最后应说明的是：以上所述仅为本发明的优选实施例而已，并不用于限制本发明，尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (4)
1.含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用。
2.如权利要求1所述的应用，其特征在于，所述的含菊粉的益生元包括菊粉、低聚半乳糖、β－葡聚糖、低聚果糖、维生素C、维生素B2、维生素B6。
3.如权利要求1所述的应用，其特征在于，所述的含菊粉的益生元包括以下重量份数的各组分：
菊粉250～300份、低聚半乳糖100～150份、β－葡聚糖80～120份、低聚果糖80～120份、维生素C 30-80份、维生素B2 3～8份和维生素B6 3～8份。
4.如权利要求1所述的应用，其特征在于，所述的含菊粉的益生元包括以下重量份数的各组分：
菊粉280份、低聚半乳糖120份、β－葡聚糖100份、低聚果糖100份、维生素50份、维生素B25份和维生素B6 5份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111025423.5A CN113712992A (zh) | 2021-09-02 | 2021-09-02 | 含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111025423.5A CN113712992A (zh) | 2021-09-02 | 2021-09-02 | 含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113712992A true CN113712992A (zh) | 2021-11-30 |
Family
ID=78680898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111025423.5A Pending CN113712992A (zh) | 2021-09-02 | 2021-09-02 | 含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113712992A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107140723A (zh) * | 2017-07-06 | 2017-09-08 | 杨永利 | 一种用于治疗糖尿病的富氢水产生装置 |
| CN107898920A (zh) * | 2017-11-22 | 2018-04-13 | 中山市择朋生物科技有限公司 | 一种用于糖尿病的口含制品与制备方法 |
| CN112402464A (zh) * | 2020-12-14 | 2021-02-26 | 山东第一医科大学附属内分泌与代谢病医院 | 一种有益于2型糖尿病患者的复合益生菌组合物 |
| CN113274481A (zh) * | 2021-05-28 | 2021-08-20 | 湖北明德医疗科技有限责任公司 | 一种用于调节血糖的组合物及其制备方法和应用 |
-
2021
- 2021-09-02 CN CN202111025423.5A patent/CN113712992A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107140723A (zh) * | 2017-07-06 | 2017-09-08 | 杨永利 | 一种用于治疗糖尿病的富氢水产生装置 |
| CN107898920A (zh) * | 2017-11-22 | 2018-04-13 | 中山市择朋生物科技有限公司 | 一种用于糖尿病的口含制品与制备方法 |
| CN112402464A (zh) * | 2020-12-14 | 2021-02-26 | 山东第一医科大学附属内分泌与代谢病医院 | 一种有益于2型糖尿病患者的复合益生菌组合物 |
| CN113274481A (zh) * | 2021-05-28 | 2021-08-20 | 湖北明德医疗科技有限责任公司 | 一种用于调节血糖的组合物及其制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| KAMIMURA N等: ""Molecular hydrogen improves obesity and diabetes by inducing hepatic FGF21 and stimulating energy metabolism in db/db mice"", 《OBESITY》 * |
| 范青生: "《保健食品配方原理与依据》", 31 January 2007, 中国医药科技出版社 * |
| 黄伟、李长山: "《好水喝出健康来 健康的电解还原水》", 31 January 2014, 《好水喝出健康来 健康的电解还原水》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106616187A (zh) | 一种辅助降三高的固体饮料 | |
| TWI721248B (zh) | 提高耐力表現之抗疲勞組合物 | |
| CN110623182A (zh) | 一种用于治疗高尿酸及痛风的益生菌植物固体饮料 | |
| CN113274481B (zh) | 一种用于调节血糖的组合物及其制备方法和应用 | |
| Hartajanie et al. | Probiotics fermented bitter melon juice as promising complementary agent for diabetes type 2: study on animal model | |
| KR20140090453A (ko) | 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물 | |
| CN113874024A (zh) | 包含2’-岩藻糖基乳糖和gos的组合物 | |
| EP2143719A1 (en) | Pharmaceutical composition, food or beverage capable of enhancing sympathetic nerve activity | |
| CN109221519A (zh) | 一种降血糖用低聚糖益生菌固体饮料及其制备方法 | |
| JP2016506381A (ja) | シクロデキストリンを含むカテキン生体利用率増進剤 | |
| WO2015170881A1 (ko) | 혈행개선 또는 모세혈관 활성증가용 건강 기능성 식품 조성물 | |
| US20100179089A1 (en) | Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly | |
| Luo et al. | Research progress of konjac dietary fibre in the prevention and treatment of diabetes | |
| JP2007051135A (ja) | Ｄ−アロースの血糖上昇抑制効果の利用 | |
| CN108378355A (zh) | 降低2型糖尿病患者餐后血糖改善血脂增加肠道有益菌的餐前预营养组合物及其制备方法 | |
| CN113712992A (zh) | 含菊粉的益生元与富氢水联用在制备血糖控制药物中的应用 | |
| CN106360735A (zh) | 一种辅助降血糖降血脂的食品组合物 | |
| CN110638842A (zh) | 一种改善高血糖的益生菌组合物 | |
| CN114533848A (zh) | 降糖、控糖的谷果植物肽压片糖果 | |
| CN113893262A (zh) | 一种用于干预糖尿病前期空腹血糖偏高的nad+组合物及其制备方法和使用方法 | |
| CN110876717A (zh) | 一种可稳定血糖制品的制备方法 | |
| CN113115874A (zh) | 一种含益生元的果汁及其制备方法 | |
| CN115299614B (zh) | 一种解酒组合物、解酒果冻及其制备方法与应用 | |
| TW201938042A (zh) | 腸道屏障功能改善用組成物 | |
| CN111214641A (zh) | 一种用于治疗糖尿病的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211130 |